These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 33489083)

  • 61. Comprehensive identification of delusions and olfactory, tactile, gustatory, and minor hallucinations in Parkinson's disease psychosis.
    Kulick CV; Montgomery KM; Nirenberg MJ
    Parkinsonism Relat Disord; 2018 Sep; 54():40-45. PubMed ID: 29653909
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinical characteristics and treatment of psychosis in Parkinson's disease: A narrative review.
    Stamenović J; Živadinović B; Đurić V
    J Chin Med Assoc; 2024 Aug; ():. PubMed ID: 39118220
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mortality Among Parkinson's Disease Patients Treated With Pimavanserin or Atypical Antipsychotics: An Observational Study in Medicare Beneficiaries.
    Mosholder AD; Ma Y; Akhtar S; Podskalny GD; Feng Y; Lyu H; Liao J; Wei Y; Wernecke M; Leishear K; Nelson LM; MaCurdy TE; Kelman JA; Graham DJ
    Am J Psychiatry; 2022 Aug; 179(8):553-561. PubMed ID: 35702829
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study.
    Ballard C; Banister C; Khan Z; Cummings J; Demos G; Coate B; Youakim JM; Owen R; Stankovic S;
    Lancet Neurol; 2018 Mar; 17(3):213-222. PubMed ID: 29452684
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of psychosis in Parkinson's disease: safety considerations.
    Fernandez HH; Trieschmann ME; Friedman JH
    Drug Saf; 2003; 26(9):643-59. PubMed ID: 12814332
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Treatment of psychosis and dementia in Parkinson's disease.
    Goldman JG; Holden S
    Curr Treat Options Neurol; 2014 Mar; 16(3):281. PubMed ID: 24464490
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Psychosis in Parkinson's Disease: A Lesson from Genetics.
    Angelopoulou E; Bougea A; Papageorgiou SG; Villa C
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741861
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Pimavanserin in Parkinson's Disease-induced Psychosis: A Literature Review.
    Patel RS; Bhela J; Tahir M; Pisati SR; Hossain S
    Cureus; 2019 Jul; 11(7):e5257. PubMed ID: 31572642
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Motor- and cognition-related safety of pimavanserin in patients with Parkinson's disease psychosis.
    Abler V; Brain C; Ballard C; Berrio A; Coate B; Espay AJ
    Front Neurol; 2022; 13():919778. PubMed ID: 36277907
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of psychosis in Parkinson's disease and dementia with Lewy Bodies: A review.
    Kyle K; Bronstein JM
    Parkinsonism Relat Disord; 2020 Jun; 75():55-62. PubMed ID: 32480308
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Treatment of psychotic symptoms in patients with Parkinson disease.
    Chen JJ
    Ment Health Clin; 2017 Nov; 7(6):262-270. PubMed ID: 29955532
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term evaluation of open-label pimavanserin safety and tolerability in Parkinson's disease psychosis.
    Ballard CG; Kreitzman DL; Isaacson S; Liu IY; Norton JC; Demos G; Fernandez HH; Ilic TV; Azulay JP; Ferreira JJ; Abler V; Stankovic S;
    Parkinsonism Relat Disord; 2020 Aug; 77():100-106. PubMed ID: 32712560
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Atypical antipsychotics for Parkinson's disease psychosis: a systematic review and meta-analysis.
    Zhang H; Wang L; Fan Y; Yang L; Wen X; Liu Y; Liu Z
    Neuropsychiatr Dis Treat; 2019; 15():2137-2149. PubMed ID: 31551655
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
    Longardner K; Wright BA; Alakkas A; You H; Xu R; Liu L; Nahab FB
    PLoS One; 2023; 18(1):e0278262. PubMed ID: 36706079
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Advances in Management of Psychosis in Neurodegenerative Diseases.
    Rothenberg KG; Rajaram R
    Curr Treat Options Neurol; 2019 Jan; 21(1):3. PubMed ID: 30673880
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.
    Wilby KJ; Johnson EG; Johnson HE; Ensom MHH
    Ann Pharmacother; 2017 Aug; 51(8):682-695. PubMed ID: 28385039
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Long-term outcomes with pimavanserin for psychosis in clinical practice.
    Akbar U; Friedman JH
    Clin Park Relat Disord; 2022; 6():100143. PubMed ID: 35479873
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Parkinson disease psychosis: Update.
    Friedman JH
    Behav Neurol; 2013 Jan; 27(4):469-77. PubMed ID: 23242358
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.
    Samudra N; Patel N; Womack KB; Khemani P; Chitnis S
    Drugs Aging; 2016 Dec; 33(12):855-863. PubMed ID: 27830568
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Current Understanding of Psychosis in Parkinson's Disease.
    Ojo OO; Fernandez HH
    Curr Psychiatry Rep; 2016 Oct; 18(10):97. PubMed ID: 27629356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.